Policy | September 16, 2025
FDA launches crackdown on deceptive drug advertising
The FDA is beginning rulemaking to close the “adequate provision” loophole
The FDA is beginning rulemaking to close the “adequate provision” loophole
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
7-OH is a concentrated byproduct of the kratom plant and has shown potential for abuse by binding to opioid receptors
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
Acquisition expands Merck’s growing hematology portfolio
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
Subscribe To Our Newsletter & Stay Updated
